Crohn's Disease Pipeline 2025: A Comprehensive Overview of Emerging Therapies and Treatment Options

Crohn's disease is a chronic inflammatory condition that affects the gastrointestinal tract, causing inflammation and symptoms such as abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. Despite current treatments, there is still a need for effective therapies to manage symptoms and improve quality of life for patients. DelveInsight's Crohn's Disease Pipeline Report provides a comprehensive overview of emerging therapies and treatment options, highlighting key companies, mechanisms of action, and clinical trials evaluation.

The report highlights that globally, the Crohn's Disease pipeline constitutes 40+ key companies working towards developing 50+ Crohn's Disease treatment therapies. Notable companies involved in the treatment market include Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, and others.

Key Takeaways:

• The global Crohn's Disease pipeline features 50+ products under various stages of clinical development, including late-stage products, mid-stage products, early-stage products, pre-clinical, and discovery stage candidates, as well as discontinued and inactive candidates.
• Emerging Crohn's Disease therapies, such as MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others, are expected to have a significant impact on the Crohn's Disease market in the coming years.
• Pharmaceutical companies like Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, and others are actively involved in the development of Crohn's Disease therapies.
• Key Molecule types for Crohn's Disease treatment include Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy.
• The report also explores various Routes of Administration for Crohn's Disease therapies, including Oral, Parenteral, Intravenous, Subcutaneous, and Topical.

Statistics:

• The global Crohn's Disease pipeline constitutes 40+ key companies working towards developing 50+ Crohn's Disease treatment therapies.
• The report highlights that 50+ products are under various stages of clinical development for Crohn's Disease treatment.
• As of 2025, there are approximately 40+ key companies involved in the treatment market for Crohn's Disease.
• Emerging Crohn's Disease therapies, such as MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others, are expected to have a significant impact on the Crohn's Disease market in the coming years.
• The report also highlights that Company-company collaborations, Licensing agreements, and Financing details for future advancement of the Crohn's Disease market.